Source: Globe Newswire Journey Medical Corporation, a Fortress Biotech, Inc. (FBIO) company, launched Targadox™ (doxycycline hyclate USP) 50 mg film coated tablets indicated as adjunctive therapy for the treatment of severe acne. Targadox™ is the only 50 mg immediate-release doxycycline hyclate tablet currently available on the market. Targadox™ is available…...
Eli Lilly’s new psoriasis treatment Taltz launches first ads, chasing Novartis’ Cosentyx lead
Source: Playing catch-up in the next-gen psoriasis market, Eli Lilly is going all out with its first ad campaign for Taltz, promising “a chance at completely clear skin.” In Lilly’s crosshairs? Novartis’ Cosentyx, which has had a 14-month lead in getting to market first with an IL-17 inhibitor. In the…...
Samsung Biologics Korean IPO to Raise as Much as $2 Billion
Source: Bloomberg Samsung Biologics Co. is seeking to raise as much as 2.25 trillion won ($2 billion) from a South Korean initial public offering, taking an important step toward its goal of becoming the world’s largest contract manufacturer of biological medicines. The listing of the business, which makes complex drugs…...
IPO pop! Durham pharmaceutical firm Novan stock skyrockets 70%
Source: WRAL TechWire Durham-based Novan goes public at $11 a share - and its stock shows plenty of "pop," surging more than 70 percent just ahead of the market close Wednesday. Novan priced its IPO at about $44 million, down from an earlier target of $60 million. But when trading…...
Allergan to Buy Vitae Pharmaceuticals for $639 Million
Source: Allergan PLC agreed to acquire clinical-stage biotechnology company Vitae Pharmaceuticals Inc. for $639 million, more than double its market value, in a move aimed at strengthening the drugmaker’s skin-care pipeline. The price values Vitae at $21 a share, compared with the company’s closing price of $8.10 on Tuesday. Vitae…...
Horizon Pharma to buy Raptor Pharma for $800 mln
Source: Horizon Pharma Plc (HZNP.O) said it would buy Raptor Pharmaceutical Corp (RPTP.O) for nearly $800 million to bolster its portfolio of drugs to treat rare diseases and reduce its dependence on the primary care market. The deal will give Horizon drugs used to treat diseases including rare metabolic disorders…...
Celgene off-label marketing lawsuit documents unsealed
Source: Celgene ($CELG) has successfully fought off several lawsuits suggesting the success of its blockbuster multiple myeloma meds Revlimid and Thalomid relied on aggressive off-label marketing. A California whistleblower case, however, has moved forward with the unsealing of thousands of pages of new documents that attorneys for a former sales…...
Dermatology biotech Novan goes for $60M IPO
Source: FierceBiotech The late-stage skin condition biotech Novan is looking to batter ongoing headwinds and gun for a $60 million public offering. The Durham, NC-based company, which is around a decade old, is working on nitric oxide based therapies for dermatologic indications, including acne. According to its SEC-1 filing, the…...
Allergan’s newest Kybella targets? Bra-line, ankle fat
Source: Allergan ($AGN) thinks facial injectable Kybella has the potential to one day bank Botox-level sales. And the company is starting up a couple new studies to help it get there. The Dublin drugmaker is initiating trials of the med in bra-line fat and fat around the knees and ankles,…...
Valeant under criminal investigation over Philidor ties: WSJ
Source: Reuters U.S. prosecutors have opened a criminal investigation into Valeant Pharmaceuticals International Inc (VRX.N) over whether it hid from insurers its relationship with a specialty pharmacy that helped boost its drug sales, the Wall Street Journal reported on Wednesday. Lawyers at the U.S. Attorney's Manhattan office are trying to…...